Neomed Bioscience Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 16-11-2024
- Paid Up Capital ₹ 0.10 M
as on 16-11-2024
- Company Age 10 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -27.63%
(FY 2023)
- Profit 21.33%
(FY 2023)
- Ebitda -146.06%
(FY 2023)
- Net Worth 10.60%
(FY 2023)
- Total Assets 10.93%
(FY 2023)
About Neomed Bioscience
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Rahul Chordia and Rupesh Chordia serve as directors at the Company.
- CIN/LLPIN
U36999PN2014PTC152235
- Company No.
152235
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Aug 2014
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Neomed Bioscience Private Limited offer?
Neomed Bioscience Private Limited offers a wide range of products and services, including Digestive System Drugs & Medicines, Antiemetic, TB, Tumor & Cancer Drugs, Anti Cancer Injection, Common Disease Medicines, Injectable Products, Anti Cancer Medicines, Medical Surgery & Treatment Centres, Medical Treatment Services, Anti Infective Drugs & Medicines.
Who are the key members and board of directors at Neomed Bioscience?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rupesh Chordia  | Additional Director | 30-Mar-2021 | Current |
| Rahul Chordia | Director | 20-Aug-2014 | Current |
Financial Performance of Neomed Bioscience.
Neomed Bioscience Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 27.63% decrease. The company also saw a substantial improvement in profitability, with a 21.33% increase in profit. The company's net worth Soared by an impressive increase of 10.6%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Neomed Bioscience?
In 2023, Neomed Bioscience had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Neomed Bioscience?
Unlock and access historical data on people associated with Neomed Bioscience, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Neomed Bioscience, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Neomed Bioscience's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
